Navigation Links
Polaris Group Files New IND for ADI-PEG 20 in Leukemia
Date:12/2/2013

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia. The FDA has reviewed this application, waived the 30-day review period and allowed treatment to begin. Polaris Group has previously filed other INDs under which it is conducting clinical trials on ADI-PEG 20 for the treatment of multiple other indications, including metastatic melanoma, prostate cancer, and hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.

"This is another IND that expands the portfolio of indications for which ADI-PEG 20 is under development to hematologic malignancies," said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Group. "Studies in leukemia and lymphoma will expand the studies currently underway with ADI-PEG 20, in addition to the solid tumors already under study. ADI-PEG 20 has a novel mechanism of action and well documented tolerability that we believe makes ADI-PEG 20 an ideal candidate both as monotherapy and to combine with other agents, including cytotoxics."

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com


'/>"/>
SOURCE Polaris Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Millennium HealthCare Inc. Installs VasoScan Cardiovascular Assessment Test in Select Physician Groups during First Week of Launch
4. The Huntzinger Management Group, Inc. (HMG) Reporting Significant Growth and Business Expansion in 2013
5. Jean Coutu Group chooses Microsoft Dynamics for Retail to streamline operations
6. Life Care Solutions Group: The #Vaginal Mesh Debacle Is More Complicated Then The Hip Settlement
7. Implantable Medical Device Group formed to Reduce Risk and Simplify Management of Active Implant Projects
8. Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
9. HyGreen, Inc. Signs Distribution Agreement with Unison Group
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
11. Triangle Insights Group Opens RTP Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin ... pure essential oils, announced the company had a successful visit to the 2017 ECRM ... event gives companies that work in the nutritional, sports and health industries a chance ...
(Date:1/20/2017)... ... , ... Lice Troopers, the lice removal company based in South Florida, has ... holiday season. , “It happens every year around this time,” says owner, Arie ... which is the head-to-head gateway that lice need to spread.” , As children return ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
Breaking Medicine News(10 mins):